Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Siren Song Of Lupus Has Left A Legacy Of Failed Trials

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The five-decade drought in FDA approvals of lupus therapies – broken by Human Genome Sciences Inc.'s recent launch of Benlysta – featured a steady stream of drug developers that were not dissuaded by the legacy of trial failures and shifting regulatory standards that marked the field, only to join the ranks of clinical failures in lupus.

You may also be interested in...



FDA’s Benlysta Approval: A Lesson In Overcoming Unvalidated Endpoints

A novel composite primary endpoint created by Human Genome Sciences with FDA’s blessing helped Benlysta (belimumab) obtain approval for lupus – one of contemporary drug development’s most challenging indications – despite the absence of a standard disease outcome measure.

FDA’s Benlysta Approval: A Lesson In Overcoming Unvalidated Endpoints

A novel composite primary endpoint created by Human Genome Sciences with FDA’s blessing helped Benlysta (belimumab) obtain approval for lupus – one of contemporary drug development’s most challenging indications – despite the absence of a standard disease outcome measure.

FDA Guidances On Lupus Drug Development Call For Superiority Trials

For development of drugs for either 1systemic lupus erythematosus or 2lupus nephritis, the gold standard study design is a randomized superiority trial, using either placebo or active control with the investigational therapy as an add-on to standard of care, according to a pair of final guidances released by FDA June 21

Related Content

Topics

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel